Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-21, Stock:NVS, The news for the past five days is as follows:
2018-03-14: NEWS1: Why Intellia Therapeutics Is Plunging Today.NEWS2: Why Intellia Therapeutics Is Plunging Today.NEWS3: Why Intellia Therapeutics Is Plunging Today.NEWS4: How Novartis’s Sandoz Performed in 4Q17.NEWS5: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS6: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS7: The Swiss Stock Market Dipped On Disappointing U.S. Data.NEWS8: The Swiss Stock Market Dipped On Disappointing U.S. Data.NEWS9: Novartis’s Innovative Medicines Business in 4Q17.NEWS10: What Analysts Recommend for AstraZeneca in March 2018.NEWS11: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS12: How Novartis’s Business Segments Performed in 4Q17.NEWS13: What Analysts Expect for AstraZeneca Going Forward.
2018-03-15: NEWS1: Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping.NEWS2: Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping.NEWS3: What Analysts Recommend for Novartis in March 2018.NEWS4: How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment.NEWS5: How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment.NEWS6: Must-Know Recent Developments from Novartis.NEWS7: How Novartis’s Alcon Performed in 4Q17.NEWS8: Swiss Pharma Gets a Taste of Silicon Valley.
2018-03-16: NEWS1: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS2: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS3: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS4: The Swiss Stock Market Finished Nearly Flat In Directionless Trade.NEWS5: The Swiss Stock Market Finished Nearly Flat In Directionless Trade.
2018-03-19: NEWS1: GlaxoSmithKline’s Valuation in March 2018.NEWS2: Is Novartis (NVS) a Suitable Stock for Value Investors Now?.NEWS3: Is Novartis (NVS) a Suitable Stock for Value Investors Now?.NEWS4: VGK, FEU: Big ETF Outflows.NEWS5: VGK, FEU: Big ETF Outflows.NEWS6: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.NEWS7: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.NEWS8: Is Novartis (NVS) a Suitable Stock for Value Investors Now?.NEWS9: The Swiss Stock Market Begins The Week With A Loss.NEWS10: The Swiss Stock Market Begins The Week With A Loss.NEWS11: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.
2018-03-20: NEWS1: Novartis Sales Reps Will Testify About Lavish Meals, U.S. Says.NEWS2: The Swiss Stock Market Recovered Some Lost Ground.NEWS3: The Swiss Stock Market Recovered Some Lost Ground.NEWS4: Novartis Partners With Harvard To Develop Biomaterial Systems.NEWS5: Novartis Partners With Harvard To Develop Biomaterial Systems.

Answer: Decrease